<乌鸦传媒>Major Survival Gain With Immunotherapy in Lymphomatoid Granulomatosis Median overall survival reached 20 years with interferon alfa-2b in low-grade disease Apr 05, 2023
<乌鸦传媒>FDA Greenlights First Drug for Rare Immunodeficiency Disease Activated PI3K-delta syndrome may have a new standard of care Mar 27, 2023
<乌鸦传媒>Make the Diagnosis: This Bump on His Nose is a Tricky Diagnosis A 52-year-old man visited his doctor for a new growth on his nose. Can you diagnosis the patient? Mar 27, 2023
<乌鸦传媒>Sam Neill's Rare Lymphoma The actor noticed swollen glands while on tour for "Jurassic World Dominion" Mar 23, 2023
<乌鸦传媒>Sickle Cell Disease Patients Miss Out on Decades of Life What effects might emerging therapies have on real-world survival? Mar 17, 2023
<乌鸦传媒>FDA Panel Endorses New First-Line Lymphoma Regimen POLARIX trial supports a favorable risk-benefit profile for polatuzumab vedotin, ODAC members say Mar 10, 2023
<乌鸦传媒>FDA Not Quite Sold on Polivy in Frontline Large B-Cell Lymphoma Regimen Ahead of ODAC meeting, agency reviewers suggest modest PFS results in POLARIX "raise uncertainty" Mar 07, 2023
<乌鸦传媒>Full-Dose Anticoagulation Again Favored for COVID Admissions Despite failures, FREEDOM trial supports mortality advantage in general ward use Mar 07, 2023
<乌鸦传媒>Cases of Breast Implant-Associated Lymphoma Continue to Accumulate More than 1,300 cases and 35 deaths, as reports of other implant-linked malignancies emerge Mar 06, 2023
<乌鸦传媒>'Winners' and 'Losers'; Mandated Sick Leave and Cancer Screening; More AI Advances News, features, and commentary about cancer-related issues Mar 03, 2023
<乌鸦传媒>Cancer Drugs That Didn't Work; Another HIV Cure; Kiss of Success With Mistletoe News, features, and commentary about cancer-related issues Feb 24, 2023
<乌鸦传媒>Gene Tx Shows Sustained Bleeding Control in Severe Hemophilia A at 2 Years Model predicts valoctocogene roxaparvovec could maintain mild hemophilia levels for 5 years Feb 23, 2023
<乌鸦传媒>Targeted Agents Go Head-to-Head for Newly Diagnosed Ph+ ALL Trial crowns a winner, but how relevant is it amid the changing therapeutic landscape for ALL? Feb 16, 2023
<乌鸦传媒>The 'Extreme' Story of How Two Game-Changing Cancer Drugs Came to Market New book by former Forbes senior editor pulls back the curtain on drug development Feb 13, 2023
<乌鸦传媒>Novel 'Off the Shelf' CAR-T Product Shows Promise in Myeloma Researchers say safety, efficacy of ALLO-715 comparable to autologous anti-BCMA products Feb 02, 2023
<乌鸦传媒>New Class of Factor VIII Replacement Therapy Prevents Bleeds in Severe Hemophilia A Weekly dosing with efanesoctocog alfa reduced annualized bleeding rate by 77% Jan 25, 2023
<乌鸦传媒>Inflammatory VEXAS Syndrome May Not Be So Uncommon Is new disease being missed by physicians? Jan 24, 2023
<乌鸦传媒>Epstein-Barr Virus Tracking After Liver Transplant May Cut Rare Complication Observational study provides suggestive evidence Jan 17, 2023
<乌鸦传媒>Off-the-Shelf T-Cell Therapy Effective Against Viral Infections After Allo-HCT Produced an antiviral response in 95% of patients with six different types of infection Jan 13, 2023
<乌鸦传媒>Zanubrutinib Shows Good Tolerance in BTK-Inhibitor Intolerant Malignancies Most patients had no recurrence of their original intolerance event Jan 10, 2023
<乌鸦传媒>Post-HSCT Brentuximab Vedotin Plus Nivolumab Highly Effective in Hodgkin Lymphoma However, toxic effects might limit the combination to the highest-risk patients Jan 10, 2023
<乌鸦传媒>Crystal Ball Cloudy for PI3K Inhibitors' Future in Hematology After a year of negative news, some caution about throwing out the baby with the bath water Jan 02, 2023
<乌鸦传媒>Early Win for Gene Therapy in Rare Form of SCID 10 infants were able to make their own T cells; safety good so far Dec 21, 2022
<乌鸦传媒>Anti-PD-1 Drugs Impress as Frontline Therapy for Early, Unfavorable Hodgkin's 3-year PFS of 99%, OS of 100% with nivolumab-chemo, high response rate with pembrolizumab Dec 16, 2022
<乌鸦传媒>New Regimen for GvHD Prophylaxis in Well-Matched Reduced-Intensity Allo-HCT Post-transplant cyclophosphamide, tacrolimus, and MMF reduces GvHD without higher relapse risk Dec 14, 2022
<乌鸦传媒>'Practice-Changing' Results With Zanubrutinib Versus Ibrutinib in CLL/SLL Significantly longer PFS with second-gen BTK inhibitor in relapsed/refractory disease Dec 14, 2022
<乌鸦传媒>C3 Pathway Inhibitor May Change Practice for Paroxysmal Nocturnal Hemoglobinuria Iptacopan improved hemoglobin without transfusion versus current standard of care Dec 14, 2022
<乌鸦传媒>Blinatumomab-Chemo Consolidation a 'New Standard' in MRD-Negative B-ALL Phase III study showed 58% reduction in the risk of death versus chemo alone Dec 13, 2022
<乌鸦传媒>Durable Platelet Response in Immune Thrombocytopenia With Efgartigimod Glycoprotein receptor inhibitor produces four times as many responses as placebo Dec 12, 2022
<乌鸦传媒>Black Patients Less Likely to Get Advanced Treatments for PE Also less likely for patients on Medicare and Medicaid Dec 12, 2022
<乌鸦传媒>AML Study Suggests Intensive Chemo Unnecessary Before Allo-HCT Similar outcomes if patients went directly to transplant or received intensive salvage first Dec 11, 2022
<乌鸦传媒>Talquetamab Offers New Hope in Relapsed/Refractory Multiple Myeloma Bispecific antibody achieves "incredible" response rates over 70% in heavily pretreated patients Dec 11, 2022
<乌鸦传媒>Ibrutinib Makes Its Case for First-Line Treatment in Mantle Cell Lymphoma Standard-of-care autologous transplant fails to prove superior to BTK inhibitor alone Dec 11, 2022
<乌鸦传媒>Rigid In-Hospital Diet Offers No Advantage in Patients After HSCT "We should eliminate these silly neutropenic diets," expert says Dec 10, 2022
<乌鸦传媒>New IDH1 Inhibitor Wins FDA Approval for Acute Myeloid Leukemia Olutasidenib led to a 35% response rate in a study of adults with previously treated AML Dec 02, 2022
<乌鸦传媒>FDA OKs First Gene Therapy for Hemophilia B Hemgenix reduced rate of annual bleeds, eliminated need for factor IX prophylaxis therapy Nov 22, 2022
<乌鸦传媒>Lenalidomide-Induced Second Cancer Risk Limited to Multiple Myeloma No increased risk to patients with other hematologic malignancies, meta-analysis shows Nov 02, 2022
<乌鸦传媒>Study: U.S. Chemo Regimen for Ewing Sarcoma Should Be International Standard Europe and other countries have already followed suit Nov 01, 2022
<乌鸦传媒>FDA Broadens Options for Relapsed/Refractory Multiple Myeloma With Teclistamab Bispecific antibody achieved durable responses in a majority of heavily pretreated patients Oct 25, 2022
<乌鸦传媒>Transplant With Orca-T Reduced GVHD in Hematologic Malignancies Risk of relapse was also lower in the group who received the cell therapy Oct 03, 2022
